Angiogenic and Antiangiogenic Factors in Preterm Neonates Born to Mothers with and without Preeclampsia

Cláudia R. Hentges; Rita C. Silveira; Renato S. Procianoy

doi:10.1055/s-0035-1552932

American Journal of Perinatology, Inhaltsverzeichnis

Am J Perinatol 2015; 32(12): 1185-1190
DOI: 10.1055/s-0035-1552932

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Angiogenic and Antiangiogenic Factors in Preterm Neonates Born to Mothers with and without Preeclampsia

Cláudia R. Hentges

¹Department of Pediatrics, Newborn Section, Universidade Federal do Rio Grande do Sul and Hospital de Clínicas de Porto Alegre, Porto Alegre-RS, Brazil

,

Rita C. Silveira

¹Department of Pediatrics, Newborn Section, Universidade Federal do Rio Grande do Sul and Hospital de Clínicas de Porto Alegre, Porto Alegre-RS, Brazil

,

Renato S. Procianoy

¹Department of Pediatrics, Newborn Section, Universidade Federal do Rio Grande do Sul and Hospital de Clínicas de Porto Alegre, Porto Alegre-RS, Brazil

› Institutsangaben

Abstract

Background Angiogenic and antiangiogenic factors are altered in pregnant women with preeclampsia (PE), but the pattern of expression of these factors in their newborns remains unknown.

Objective This study aims to measure vascular endothelial growth factor (VEGF) and soluble fms-like tyrosine kinase 1 (sFlt-1) levels in preterm neonates born to mothers with PE.

Methods Neonates with birth weight < 2,000 g and gestational age ≤ 34 weeks were included and divided into the following two groups: born to mothers with PE and without PE. Blood was collected from neonates within the first 72 hours of life. VEGF and sFlt-1 levels were measured using the enzyme-linked immunosorbent assay method.

Results A total of 88 neonates were included (37 born to mothers with PE and 51 born to mothers without PE), with a mean gestational age of 29.12 ± 2.96 weeks and birth weight of 1,223.80 ± 417.48 g. In the multivariate analysis, VEGF was 80% lower and sFlt-1 was 13.48 times higher in the group with PE. sFlt-1 concentration was higher in neonates small for gestational age (SGA) than in those appropriate for gestational age.

Conclusion Higher sFlt-1 and lower VEGF levels in the group with PE, as well as higher sFlt-1 levels in SGA neonates, reflect a predominance of antiangiogenic mechanisms in PE and growth restriction.

Keywords

angiogenic factors - preeclampsia - prematurity - VEGF - sFlt-1 - antiangiogenic factors

Volltext

Referenzen

References
1 Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am 2010; 37 (2) 239-253
2 Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005; 46 (5) 1077-1085
3 Muy-Rivera M, Vadachkoria S, Woelk GB, Qiu C, Mahomed K, Williams MA. Maternal plasma VEGF, sVEGF-R1, and PlGF concentrations in preeclamptic and normotensive pregnant Zimbabwean women. Physiol Res 2005; 54 (6) 611-622
4 Cerdeira AS, Karumanchi SA. Angiogenic factors in preeclampsia and related disorders. Cold Spring Harb Perspect Med 2012; 2 (11) pii: a006585
5 Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 2008; 11 (3) 215-221
6 Hentges CR, Silveira RC, Ferrelli RS, Procianoy RS. Influence of maternal pre-eclampsia on VEGF/PlGF heterodimer levels in preterm infants. J Matern Fetal Neonatal Med 2014; 14: 1-6
7 Catarino C, Rebelo I, Belo L , et al. Fetal and maternal angiogenic/anti-angiogenic factors in normal and preeclamptic pregnancy. Growth Factors 2009; 27 (6) 345-351
8 Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during preeclampsia. Eur J Obstet Gynecol Reprod Biol 2005; 122 (1) 33-39
9 Rana S, Karumanchi SA, Levine RJ , et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50 (1) 137-142
10 Erez O, Romero R, Espinoza J , et al. The change in concentrations of angiogenic and antiangiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21 (5) 279-287
11 Maynard SE, Min JY, Merchan J , et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111 (5) 649-658
12 Levine RJ, Maynard SE, Qian C , et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350 (7) 672-683
13 Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007; 196 (3) 239.e1-239.e6
14 Troisi R, Braekke K, Harsem NK, Hyer M, Hoover RN, Staff AC. Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies. Am J Obstet Gynecol 2008; 199 (6) 653.e1-653.e10
15 Levine RJ, Lam C, Qian C , et al; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355 (10) 992-1005
16 Staff AC, Harsem NK, Braekke K, Hyer M, Hoover RN, Troisi R. Maternal, gestational and neonatal characteristics and maternal angiogenic factors in normotensive pregnancies. Eur J Obstet Gynecol Reprod Biol 2009; 143 (1) 29-33
17 Sunderji S, Gaziano E, Wothe D , et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010; 202 (1) 40.e1-40.e7
18 Furuya M, Kurasawa K, Nagahama K , et al. Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia. J Pregnancy 2011; 2011: 123717
19 Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365 (9461) 785-799
20 Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996; 87 (2) 163-168
21 Zin A, Florêncio T, Fortes Filho JB , et al; Brazilian Society of Pediatrics, Brazilian Council of Ophthalmology and Brazilian Society of Pediatric Ophthalmology. Brazilian guidelines proposal for screening and treatment of retinopathy of prematurity (ROP). Arq Bras Oftalmol 2007; 70 (5) 875-883
22 Pieh C, Agostini H, Buschbeck C , et al. VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity. Br J Ophthalmol 2008; 92 (5) 689-693
23 Eklund A. Beeswarm: The bee swarm plot, an alternative to stripchart. R package version 0.1.1, 2011. Available at: http://CRAN.R-project.org/package=beeswarm . Accessed February 2, 2015
24 Boutsikou T, Malamitsi-Puchner A, Economou E, Boutsikou M, Puchner KP, Hassiakos D. Soluble vascular endothelial growth factor receptor-1 in intrauterine growth restricted fetuses and neonates. Early Hum Dev 2006; 82 (4) 235-239
25 van Beem RT, Verloop RE, Kleijer M , et al. Blood outgrowth endothelial cells from cord blood and peripheral blood: angiogenesis-related characteristics in vitro. J Thromb Haemost 2009; 7 (1) 217-226
26 Khan I, Zhang L, Mohammed M , et al. Effects of Wharton's jelly-derived mesenchymal stem cells on neonatal neutrophils. J Inflamm Res 2015; 8: 1-8
27 Mashiloane CD, Moodley J. Induction or caesarean section for preterm pre-eclampsia?. J Obstet Gynaecol 2002; 22 (4) 353-356
28 Zhang Y, Li W, Xiao J, Chen S. The complication and mode of delivery in Chinese women with severe preeclampsia: a retrospective study. Hypertens Pregnancy 2014; 33 (3) 283-290
29 Jelin AC, Cheng YW, Shaffer BL, Kaimal AJ, Little SE, Caughey AB. Early-onset preeclampsia and neonatal outcomes. J Matern Fetal Neonatal Med 2010; 23 (5) 389-392
30 Wang A, Holston AM, Yu KF , et al. Circulating anti-angiogenic factors during hypertensive pregnancy and increased risk of respiratory distress syndrome in preterm neonates. J Matern Fetal Neonatal Med 2012; 25 (8) 1447-1452
31 Ozkan H, Cetinkaya M, Koksal N. Increased incidence of bronchopulmonary dysplasia in preterm infants exposed to preeclampsia. J Matern Fetal Neonatal Med 2012; 25 (12) 2681-2685
32 Tang JR, Karumanchi SA, Seedorf G, Markham N, Abman SH. Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2012; 302 (1) L36-L46
33 Hansen AR, Barnés CM, Folkman J, McElrath TF. Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr 2010; 156 (4) 532-536
34 Ozkan H, Cetinkaya M, Koksal N, Ozmen A, Yıldız M. Maternal preeclampsia is associated with an increased risk of retinopathy of prematurity. J Perinat Med 2011; 39 (5) 523-527
35 Tsao PN, Wei SC, Su YN, Chou HC, Chen CY, Hsieh WS. Excess soluble fms-like tyrosine kinase 1 and low platelet counts in premature neonates of preeclamptic mothers. Pediatrics 2005; 116 (2) 468-472
36 Procianoy RS, Silveira RC, Mussi-Pinhata MM , et al; Brazilian Network on Neonatal Research. Sepsis and neutropenia in very low birth weight infants delivered of mothers with preeclampsia. J Pediatr 2010; 157 (3) 434-438 , 438.e1
37 Åsvold BO, Vatten LJ, Romundstad PR, Jenum PA, Karumanchi SA, Eskild A. Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction. Am J Epidemiol 2011; 173 (6) 630-639
38 Taki A, Abe M, Komaki M , et al. Expression of angiogenesis-related factors and inflammatory cytokines in placenta and umbilical vessels in pregnancies with preeclampsia and chorioamnionitis/funisitis. Congenit Anom (Kyoto) 2012; 52 (2) 97-103
39 Malamitsi-Puchner A, Boutsikou T, Economou E , et al. Vascular endothelial growth factor and placenta growth factor in intrauterine growth-restricted fetuses and neonates. Mediators Inflamm 2005; 2005 (5) 293-297